Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
IrisMed
AddedApr 14, 2024
UpdatedJul 4, 2026
IrisMed

IrisMed

Pre-Seed

IrisMed minimizes revenue leakage and compliance risks for medical facilities and revenue cycle consultancies by creating a domain-specific AI to reduce coding errors, and manage claim denials at scale.

Overview
Compare
Fundraising
Website

Founded with the mission to revolutionize medical billing, IrisMed leverages AI-powered automation to enhance the efficiency and revenue-generating potential of healthcare billing teams. The company's vision is to streamline tedious billing tasks, such as payment posting, account receivable reconciliation, and denial management, allowing healthcare providers to focus more on patient care. IrisMed offers a suite of automation tools designed specifically for the healthcare sector, including auto-posting and medical coding solutions that ensure no claim data is overlooked.

IrisMed has attracted notable investors and industry experts who recognize the transformative potential of its technology. Among its key achievements, the company has successfully integrated its robust automation tools into various healthcare systems, significantly reducing administrative burdens and improving financial outcomes for its clients. The overall impact of IrisMed is evident in the enhanced operational efficiency and increased revenue for healthcare providers, positioning it as a vital player in the medical billing automation market.

IrisMed - Quick Facts

When was IrisMed's last funding round?

IrisMed's most recent funding round was for $20k (USD) in January 2024.

How much has IrisMed raised to-date?

As of Jan 1, 2024, IrisMed has raised a total of $20k (USD).

IrisMed - Classification

Ownership
  • Venture Capital
Technology
  • AI
Geographic Exposure
  • Americas
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Medical Billing
Tags
  • AI Operations